Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 8/20 | 0.43 |
| ▸ | ITK | Q08881 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 2/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6711660 | 0.93 | HIF1A (0.43) | HIF1AITKROCK1LRRK2GSK3B | |
| SCHEMBL6917977 | 0.92 | EPHX2 (0.37) | HIF1AITKROCK1ALDH1A1ACLY | |
| SCHEMBL6709888 | 0.89 | HIF1A (0.47) | HIF1AROCK1 | |
| SCHEMBL6710332 | 0.88 | EPHX2 (0.39) | HIF1AROCK1 | |
| SCHEMBL6710167 | 0.88 | ESR1 (0.38) | HIF1AROCK1LRRK2 | |
| SCHEMBL6711807 | 0.87 | HIF1A (0.45) | HIF1AROCK1ACLY | |
| SCHEMBL6707637 | 0.87 | HIF1A (0.39) | HIF1A | |
| SCHEMBL6710038 | 0.87 | HIF1A (0.45) | HIF1AROCK1ALDH1A1POLB | |
| SCHEMBL6710001 | 0.87 | HIF1A (0.34) | HIF1ALRRK2 | |
| SCHEMBL6709953 | 0.85 | HIF1A (0.43) | HIF1AITKROCK1ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | HIF1A 296/4885ITK 1711/4885ROCK1 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.